Adma Biologics IncのEPS 1株当たり利益

Adma Biologics IncのEPS 1株当たり利益 は何ですか。

Adma Biologics IncのEPS 1株当たり利益 は0.15です。

EPS 1株当たり利益 の定義は何ですか。



1株当たり利益(EPS) は、当社の1株当たり利益です。それは株式の希釈を考慮に入れ、 過去12ヶ月間にカウントされます。

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. Preferred stock rights have precedence over common stock. Therefore, dividends on preferred shares are subtracted before calculating the EPS. When preferred shares are cumulative, annual dividends are deducted whether or not they have been declared. Dividends in arrears are not relevant when calculating EPS. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

NASDAQのセクタHealth CareにおけるEPS 1株当たり利益 の企業と比べるAdma Biologics Inc

Adma Biologics Incは何をしますか。

adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.

Adma Biologics Incと類似のeps 1株当たり利益